JP Morgan Chase
CATX icon

JP Morgan Chase’s Perspective Therapeutics CATX Stock Holding History

JP Morgan Chase’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$167K Buy
47,138
+17,897
+61% +$67.6K ﹤0.01% 5714
2026
Q1 		$112K Buy
29,241
+1,207
+4% +$5.1K ﹤0.01% 5770
2025
Q4 		$77.1K Sell
28,034
-408,323
-94% -$1.16M ﹤0.01% 6023
2025
Q3 		$1.5M Sell
436,357
-311,710
-42% -$1.14M ﹤0.01% 4295
2025
Q2 		$2.57M Buy
748,067
+405,612
+118% +$1.07M ﹤0.01% 3717
2025
Q1 		$729K Buy
342,455
+193,410
+130% +$580K ﹤0.01% 4554
2024
Q4 		$475K Buy
149,045
+124,133
+498% +$1.01M ﹤0.01% 5071
2024
Q3 		$333K Buy
24,912
+4,844
+24% +$64.4K ﹤0.01% 5147
2024
Q2 		$200K Sell
20,068
-238,045
-92% -$3.44M ﹤0.01% 5166
2024
Q1 		$3.07M Buy
258,113
+258,065
+537,635% +$2.2M ﹤0.01% 3496
2023
Q4 		$194 Buy
48
+15
+45% +$42 ﹤0.01% 7051
2023
Q3 		$90 Buy
+33
New +$154 ﹤0.01% 6921

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

JP Morgan Chase's CATX Position: Q2 2026 in Review

JP Morgan Chase increased its Perspective Therapeutics (CATX) stake by 61% in Q2 2026, buying an estimated $67.6K and bringing the position to 47,138 shares worth $167K. The position accounts for ﹤0.01% of the portfolio, ranked #5714.

JP Morgan Chase first reported a position in CATX in Q3 2023 and has held it in 12 quarters since. The position peaked at $3.07M in Q1 2024. 132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • JP Morgan Chase held 47,138 shares of Perspective Therapeutics worth $167K as of Q2 2026.
  • JP Morgan Chase bought 17,897 Perspective Therapeutics shares in Q2 2026, an estimated $67.6K.
  • Perspective Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5714 holding.
  • JP Morgan Chase first reported a position in Perspective Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • JP Morgan Chase's Perspective Therapeutics position peaked at $3.07M in Q1 2024.
  • 132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.